Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.

Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

Abstract: An apparatus to provide white illuminating light for medical or boroscopic applications includes a first light source with a light-emitting diode to emit light with a broad spectrum, a second light source to emit monochromatic light, and a coupling device to couple light of the first light source and light of the second light source into a common beam path in order to generate illuminating light with improved color rendering.

Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.

Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.

Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.

Abstract: The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.

Abstract: The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.

Abstract: A medical apparatus to support an endoscopic investigation that includes a housing with a base surface, a front surface and a rear surface, and a light source that is positioned in the housing to generate light to illuminate an object that is to be investigated with an endoscope. In addition the medical apparatus includes a coupling device to couple a proximal end of an endoscope on the medical apparatus and to transmit light from the medical apparatus to the endoscope. The medical apparatus includes a screen, which is positioned on the front surface of the housing to observe an image taken by means of the endoscope, where the front surface and rear surface are each inclined toward the rear at an angle between 5 and 15 degrees with respect to the base surface.

Abstract: Methods for producing a mono- or multilayer composite are provided in which one or several layers are applied onto a carrier material by coating, the coated mono- or multilayer composite is dried and rolled up, and the installation is subsequently cleaned. The air circuit in the drying oven is entirely set to fresh air supply, and the drying oven is configured to be cleaned in a controlled manner. All components of the drying oven that come into contact with the product do not have to be removed during cleaning, but can be cleaned-in-place using technology integrated into the drying oven. The drying oven Outer housing is designed so that it can be lifted upwardly. All assembly parts in the drying oven interior are designed to eliminate disassembling for cleaning purposes. Transport rollers within the drying oven are designed as hollow shafts and provided with spraying nozzles.

Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.

Abstract: The invention relates to a portable device (1) for the determination of surface properties with a measurement apparatus (10) which directly determines locally the topography of a surface (8) under investigation and issues at least one measured value that is characteristic of this local topography, and with a processor apparatus which, taking account of a multiplicity of initial measured values, issues at least one result value characteristic of the global topography of the surface.

Abstract: The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.

Abstract: The present invention relates, generally, to a transgenic non-human animal model of hemophilia A, wherein the transgenic animal is deficient in endogenous Factor VIII and endogenous von Willebrand Factor, and methods to treat hereditary or acquired hemophilia A or von Willebrand Disease (VWD) by administration of exogenous human VWF.

Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.

Abstract: Provided herein are stable co-formulations of immunoglobulin and hyaluronidase that are stable to storage in liquid form at room temperature for at least 6 months and at standard refrigerator temperatures for 1-2 years. Such co-formulations can be used in methods of treating IG-treatable diseases or conditions by subcutaneous administration.

Abstract: The present invention provides a flow-through photobioreactor containing at least one thermoplastic multi-wall sheet having an upper layer and a lower layer having arranged there between at least two sidewalls, at least one inner wall and two or more end caps. Also provided is a process for the production of a biofuel with the inventive photobioreactor. The photobioreactor and process of the present invention have the following advantages: genetically engineered microbes that give higher yields cannot escape into the environment, water in the system does not evaporate, no weeding (presence of unwanted algae), UV light from the sun is filtered out by the reactor walls, temperature control is possible, CO2 from power plants, breweries, etc. can be artificially fed to increase yield. The inventive photobioreactor is also less expensive to build than pipe reactors and may have low energy costs to operate, because little or no energy is needed for agitation and pumping in a preferred gravity assisted embodiment.

Abstract: The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction.

Abstract: A method of determining properties of textured surfaces with the steps: irradiation of radiation onto the surface (10) to be investigated; detection of at least part of the radiation irradiated onto the surface (10) and reflected by the latter by means of a detector device (4) which permits a location-resolved evaluation of the radiation striking it; determination of a first characteristic value (?P) from the radiation detected, wherein the first characteristic value (?P) is characteristic of a texture of the surface (10); determination of a second characteristic value (?E) from the radiation detected, wherein the second characteristic value is characteristic of a further optical property of the surface (10); determination of a result value (?I) on the basis of the first characteristic value (?P) and the second characteristic value (?E).

Abstract: A method for the optical investigation of textured surfaces (10) with the steps: irradiation of radiation onto the surface (10) to be investigated; reception of an image from at least part of the radiation irradiated onto the surface (10) and reflected by the surface (10); location-resolved evaluation of the image recorded and determination of at least one value (K) which is characteristic of this image. According to the invention a parameter (G) which is characteristic of the surface is determined whilst using the characteristic value (K) and whilst using at least one further property (E)—known beforehand or determined—of the surface (10).